GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc.

GEHC
GE HealthCare Technologies Inc.US flagNASDAQ Global Select
69.72
USD
-0.84
- -
31.49BMarket Cap
GE HealthCare Technologies Inc.
GEHC
(NASDAQ Global Select)

Recent

price

69.72

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
36.58
37.75
38.67
44.32
42.97
43.14
45.23
46.71
Revenue per Share
3.35
30.45
4.94
4.63
3.04
4.37
4.57
4.36
Basic EPS, GAAP
3.65
3.14
2.98
4.36
3.77
3.4
3.3
3.47
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.09
0.12
0.14
0.14
Dividend per Share
- -
32.39
36.63
20.61
15.67
18.48
22.77
24.3
Book Value per Share
- -
2.76
4.21
-10.96
-15.5
-12.62
-9.3
-13.31
Tangible Book Value per Share
455
455
455
414
455
456
456
455
Basic Weighted Avg Shares
16,633
17,164
17,585
18,341
19,552
19,672
20,625
21,267
Sales/Revenue/Turnover
12.77
15.85
15.89
13.75
12.45
13.34
13.39
12.85
Operating Margin (%)
659
630
625
633
610
580
578
607
Depreciation Expense
1,524
13,846
2,247
1,916
1,568
1,993
2,084
1,984
Net Income, GAAP
19.61
24.06
20.87
22.41
31.47
20.57
22.18
22.95
Effective Tax Rate (%)
9.16
80.67
12.78
10.45
8.02
10.13
10.1
9.33
Profit Margin (%)
- -
-628
239
1,127
429
348
3,396
2,195
Working Capital
- -
336
327
8,516
8,747
7,759
9,821
10,408
LT Debt
- -
14,751
16,896
9,592
7,310
8,652
10,599
11,218
Total Equity
- -
26.64
13.37
10.86
9.3
11.67
10.83
9.84
Return on Invested Capital (%)
- -
181.95
13.72
10.86
10.7
13.28
12.06
10.59
Return on Capital (%)
- -
188.04
14.32
14.73
16.8
25.59
22.14
19.18
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
642
139
133
LT Borrowings
9,495
10,127
10,091
LT Finance Leases
326
311
317
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
456
455
452
Market Capitalization
37,380
32,379
28,912

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
12,501
10,426
10,497
Cash, Cash Equivalents & STI
4,492
2,261
2,079
Accounts Receivable, Net
3,719
3,465
3,535
Inventories
2,234
2,353
2,483
Total Current Liabilities
9,105
8,529
8,302
Payables & Accruals
3,871
3,990
3,707
ST Debt
642
139
133
Deferred Revenue
2,095
2,153
2,200

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-2.32%
22.5%
Free Cash Flow
- -
2.12%
-2.9%
Net Income, GAAP
- -
-17%
4.57%
Sales/Revenue/Turnover
- -
3.76%
4.84%
Total Cash Common Dividend
- -
- -
16.36%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,650
4,839
4,863
5,319
19,672
2025
4,777
5,006
5,144
5,698
20,625
2026
5,131
5,294
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.82
0.94
1.03
1.58
4.37
2025
1.23
1.06
0.98
1.29
4.57
2026
0.85
1.24
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.03
0.03
0.03
0.12
2025
0.04
0.04
0.04
0.04
0.14
2026
0.04
0.04
- -
- -
- -
Business
GE HealthCare Technologies Inc. specializes in the design, production, and global distribution of advanced products, extensive services, and integrated digital platforms aimed at patient diagnostics, therapeutic interventions, and ongoing monitoring across numerous international regions. The organization structures its operations into four distinct divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division delivers sophisticated molecular imaging, computed tomography (CT), magnetic resonance (MR), image-guided therapy, and X-ray systems, alongside specialized offerings for women's health screening. The Ultrasound division offers solutions for the detection, assessment, treatment, and continuous oversight of various conditions through applications in radiology, primary care, cardiovascular health, women’s health, and handheld point-of-care devices, also incorporating surgical visualization and guidance products with AI-enabled productivity tools. The Patient Care Solutions division is dedicated to furnishing medical devices, essential consumables, supportive services, and intelligent digital tools for patient monitoring, anesthesia delivery and respiratory management, diagnostic cardiology, and maternal and infant care. The Pharmaceutical Diagnostics division supplies a range of diagnostic agents, including contrast media for CT, angiography, X-ray, and MR scans, as well as single-photon emission computed tomography and positron emission tomography, to the radiology and nuclear medicine sectors. This segment also provides pharmaceuticals administered prior to imaging to enhance tissue visibility and molecular imaging agents, which are radiopharmaceuticals with radioisotopes used for diagnostic scans. The company was established as a corporate entity in 2022 and maintains its primary corporate offices in Chicago, Illinois. In a significant recent development, the company has agreed to acquire Intelerad, a medical imaging software provider, for $2.3 billion, a move set to substantially enhance its cloud-based and AI-enabled imaging solutions, particularly expanding its reach into outpatient and teleradiology markets. This acquisition is expected to accelerate GE HealthCare's transition to a software-as-a-service (SaaS) business model and significantly boost its recurring revenue.

Company News

  • GEHC Wins CE Mark for Photonova Spectra, Expands International Reach

  • GEHC vs. HAE: Which Stock Is the Better Value Option?

  • GE HealthCare Unveils Next-Gen Vivid Cardiac Ultrasound Systems

  • GE HealthCare's Photonova™ Spectra gains CE Mark, expanding international access

  • Why Is GE HealthCare (GEHC) Up 3.6% Since Last Earnings Report?

  • GE HealthCare unveils the next generation of the Vivid cardiovascular ultrasound portfolio, enabling advanced cardiac imaging across care settings

  • GE HealthCare unveils the next generation of the Vivid cardiovascular ultrasound portfolio, enabling advanced cardiac imaging across care settings

  • GE HealthCare management to present at upcoming investor conference

  • GE HealthCare management to present at upcoming investor conference

  • Bank of Nova Scotia Purchases 19,422 Shares of GE HealthCare Technologies Inc. $GEHC

  • GEHC Q2 Orders Surge 11.1% as Record Backlog Builds 2027 Visibility

  • Is GEHC a Buy Now as Growth Improves but Execution Risks Persist?

  • Here's Why You Should Add GEHC Stock to Your Portfolio for Now

  • GE HealthCare Technologies Inc. $GEHC Stock Position Increased by Barrow Hanley Mewhinney & Strauss LLC

  • GE HealthCare Technologies Inc. $GEHC Shares Sold by Allworth Financial LP

  • Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  • Bet on 4 Top-Ranked Stocks With Rising P/E

  • GE HealthCare Technologies Inc. (GEHC) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

  • Securities Fraud Investigation Into GE HealthCare Technologies Inc. (GEHC) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

  • GE HealthCare appoints William Grogan as CFO, replacing Jay Saccaro